标题
Sequencing Treatment for Castration-Resistant Prostate Cancer
作者
关键词
Prostate cancer, Metastatic castration-resistant prostate cancer, Treatment sequence
出版物
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 17, Issue 12, Pages -
出版商
Springer Nature
发表日期
2016-11-07
DOI
10.1007/s11864-016-0438-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- DNA Repair in Prostate Cancer: Biology and Clinical Implications
- (2017) Joaquin Mateo et al. EUROPEAN UROLOGY
- 791PSEQUENCING OF DOCETAXEL (D) AND ABIRATERONE ACETATE (AA) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
- (2017) Z. Zafeiriou et al. ANNALS OF ONCOLOGY
- 790PACTIVITY OF SEQUENTIAL NEW DRUGS (NDS) POST-DOCETAXEL (DOC) FAILURE, IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS). UPDATE FROM A MULTICENTER ITALIAN EXPERIENCE
- (2017) O. Caffo et al. ANNALS OF ONCOLOGY
- Comparative effectiveness of pazopanib and sunitinib as first-line therapy for patients with advanced/metastatic renal cell carcinoma in a U.S. community oncology setting.
- (2016) Bradford Richard Hirsch et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
- (2016) David F. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
- (2016) Neal D Shore et al. LANCET ONCOLOGY
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
- (2016) Howard I. Scher et al. JAMA Oncology
- Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices
- (2015) Guru Sonpavde et al. Clinical Genitourinary Cancer
- Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
- (2015) Klaus Brasso et al. EUROPEAN UROLOGY
- Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients
- (2015) Arun A. Azad et al. EUROPEAN UROLOGY
- Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
- (2015) Wendy Onstenk et al. EUROPEAN UROLOGY
- Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies
- (2015) Nader Al Nakouzi et al. EUROPEAN UROLOGY
- Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
- (2015) Orazio Caffo et al. EUROPEAN UROLOGY
- Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation
- (2015) Sergio Bracarda et al. Future Oncology
- Line of abiraterone acetate in castration-resistant metastatic prostate cancer - Does it matter? report of a multi-institutional experience
- (2015) S Gunduz et al. INDIAN JOURNAL OF CANCER
- Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302.
- (2015) Johann Sebastian De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer
- (2015) Benjamin L. Maughan et al. PROSTATE
- Line of abiraterone acetate in castration-resistant metastatic prostate cancer - Does it matter? report of a multi-institutional experience
- (2015) S Gunduz et al. INDIAN JOURNAL OF CANCER
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model
- (2015) Howard I. Scher et al. PLoS One
- Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer
- (2014) Edoardo Francini et al. ANTI-CANCER DRUGS
- Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment
- (2014) Rahul Aggarwal et al. Clinical Genitourinary Cancer
- The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
- (2014) Michael T. Schweizer et al. EUROPEAN UROLOGY
- CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel
- (2014) Michel D. Wissing et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
- (2014) Peter Hoskin et al. LANCET ONCOLOGY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer
- (2014) Arun A. Azad et al. PROSTATE
- Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone
- (2014) Daniel L. Suzman et al. PROSTATE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer
- (2011) Andrew J. Armstrong et al. EUROPEAN UROLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T
- (2010) Celestia S. Higano et al. NATURE REVIEWS DRUG DISCOVERY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now